TRDA Cash-Secured Put Strategy

TRDA (Entrada Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

TRDA (Entrada Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $297.8M, a beta of -0.26 versus the broader market, a 52-week range of 5.02-16.45, average daily share volume of 407K, a public-listing history dating back to 2021, approximately 152 full-time employees. These structural characteristics shape how TRDA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -0.26 indicates TRDA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a cash-secured put on TRDA?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

TRDA snapshot

As of August 14, 2026, spot at $7.42, ATM IV 256.50%, IV rank 53.89%, expected move 73.54%. The cash-secured put on TRDA below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this cash-secured put structure on TRDA specifically: TRDA IV at 256.50% is mid-range versus its 1-year history, so the credit collected on a TRDA cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 73.54% (roughly $5.46 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TRDA expiries trade a higher absolute premium for lower per-day decay. Position sizing on TRDA should anchor to the underlying notional of $7.42 per share and to the trader's directional view on TRDA stock.

TRDA cash-secured put setup

The TRDA cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TRDA at $7.42 on that close, the first option leg uses a $7.05 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TRDA chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TRDA shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$7.05N/A

TRDA cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

TRDA cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on TRDA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on TRDA

Cash-secured puts on TRDA earn premium while a trader waits to acquire TRDA stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning TRDA.

TRDA thesis for this cash-secured put

The market-implied 1-standard-deviation range for TRDA extends from approximately $1.96 on the downside to $12.88 on the upside. A TRDA cash-secured put lets a trader earn premium while waiting to acquire TRDA at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current TRDA IV rank near 53.89% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on TRDA should anchor more to the directional view and the expected-move geometry. As a Healthcare name, TRDA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TRDA-specific events.

TRDA cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TRDA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TRDA alongside the broader basket even when TRDA-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on TRDA carry tail risk when realized volatility exceeds the implied move; review historical TRDA earnings reactions and macro stress periods before sizing. Always rebuild the position from current TRDA chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on TRDA?
A cash-secured put on TRDA is the cash-secured put strategy applied to TRDA (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With TRDA stock at $7.42 on the most recent close, the strikes shown on this page are snapped to the nearest listed TRDA chain strike and the premiums come straight from that session's bid/ask midpoint.
How are TRDA cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the TRDA cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 256.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a TRDA cash-secured put?
The breakeven for the TRDA cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The TRDA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 73.54%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on TRDA?
Cash-secured puts on TRDA earn premium while a trader waits to acquire TRDA stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning TRDA.
How does current TRDA implied volatility affect this cash-secured put?
TRDA ATM IV is at 256.50% with IV rank near 53.89%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related TRDA analysis